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Cancer Risk Assessment and Prevention:
Where Do We Stand?
by Alice S. Whittemore*
Thispaperreviews selected aspects ofprogress and setbacks in cancerrisk assessmentandprevention dur-
ingthe four decades since the founding in 1947 ofthe Institute ofEnvironmental Medicine at the New York
University Medical Center. The period has been marked by substantial gains in quantifying the risks posed
by exposures to known human carcinogens such as tobacco and ionizing radiation. By contrast, the search
for sensitive and specific laboratory screens for human carcinogens has met setbacks, and epidemiological
datastill are needed to monitorthe adverse effects ofenvironmental exposures. Thedetermination ofacceptable
levels ofexposure topotential humancarcinogensremains afornidabletask, one forwhich no scientific fraxme-
work yetexists. Future challenges in cancerriskassessment include thevalidation anduse ofbiological mar-
kers ofexposure and effective monitoring ofrisk among exposed populations. Future challenges in cancer
prevention include the elimination oftobacco consumption and the acquisition ofknowledge needed topre-
vent nutritionally and hormonally related cancers such as cancers of the bowel, prostate, and breast.
Introduction
This year marks the fortieth anniversary of the Insti-
tute ofEnvironmental Medicine atthe New York Univer-
sity Medical Center. When the Institute began in 1947,
the Western world had just turned its attention from a
major war to domestic public healthproblems such as ur-
ban and industrial air pollution and occupational health
hazards. A few clinicians were beginning to suspect that
human cancers could be caused by exposures to tobacco,
ionizingradiation, and chemicals encountered in the work-
place. The past four decades have seen considerable re-
search focused on our interaction with the environment
and how it affects our health. The Institute of Environ-
mental Medicine has distinguished itself as a leader in
much ofthis research. At this fortieth anniversary cele-
bration it is appropriate to inquire where we stand in the
battle against environmentally induced cancer and to
identify the major unfinished tasks before us. To address
these questions, I shall review selected aspects of our
progress and setbacks in evaluating human cancer risks
from substances in the environment and describe some
of the future challenges in cancer risk assessment and
prevention. I shall use the word environment in a broad
sense, allowingit to include ways ofliving such as tobacco
use and diet.
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Detecting and Estimating
Carcinogenic Risks
I shallbegin with a discussion ofprogress andproblems
in risk estimation for two known human carcinogens:
tobacco and radiation. I shall also give a brief overview
ofprogress andproblems in monitoringriskfrom poten-
tial carcinogens-that is, substances whose carcinogenic
effect in humans is less certain.
Known Carcinogens: Tobacco
The beneficial/deleterious effects oftobacco have been
debated since its introduction to Europe in the late six-
teenth century. However, it was not until the late 1940s
that the issue was studied epidemiologically. The year
1950 saw publication ofresults from five studies compar-
ingthe smokinghabitsofpatientswithcancers ofthelung
to those ofcontrol subjects (1-5). These studies present
strongevidence ofacausal relationship. Resultsfrom sub-
sequent cohort studies and animal experiments have es-
tablished beyond reasonable doubt that cigarette smok-
ing causes cancers ofthe mouth, esophagus, respiratory
system, bladder, and pancreas. Experimental work in the
Institute of Environmental Medicine at NYU by Van
Duuren and his colleagues showed thatmanyofthe chem-
ical constituents of cigarette smoke act as carcinogens,
cocarcinogens, and promoters in mouse skin (6).A. S. WHITTEMORE
The dose response and temporal features of tobacco-
induced lung carcinogenesis are now relatively well un-
derstood. The epidemiological data indicate thatlung can-
cer death rates increase with the first or secondpower of
smoking rate and with the fourth orfifth power ofsmok-
ing duration (Figs. 1 and 2). The difference in rates be-
tween exsmokers and nonsmokers appears to remain
roughly constant in time after smoking has ceased. This
pattern, however, is less well established.
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FIGURE 1. Lung cancer incidence rates versus smoking rate in male
British physicians who were regular smokers (42).
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FIGURE 2. Lung cancer incidence rates versus duration of cigarette
smoking in male British physicians who were regular smokers and
versus age in lifelong nonsmokers. From Doll (43).
These and otherfeatures ofthe epidemiologic data have
several implications formonitoringlung cancermortality.
Theyimplythatdoublingone's daily smokingrateroughly
triples one's lung cancer risk, but that doubling one's
smokingdurationmayincrease itmore than20-fold. They
also implythat smokinghabits early inlife have a strong
effect on lung cancer rates in old age. Therefore, changes
in national lungcancerrates mustbe interpreted in terms
of tobacco consumption several decades earlier, and co-
hort effects must be considered when evaluating trends.
Figure 3 shows temporal trends in cigarette consumption
and in lungcancer death rates amongmen and women in
the United Statesfrom 1920 to 1980. The two curves are
nearly parallel. A simple linear regression ofdeath rates
against consumption 20years earlier indicates that ciga-
rette consumption explains about 93% of the temporal
variance in lung cancer mortality.
Several investigators have interpreted the temporalfea-
tures ofthe smoking-lung cancer relationship in terms of
a theory ofcarcinogenesis in which bronchial stem cells
undergo two or more heritable changes prior to generat-
ing a malignant clone (7-9). Cells in intermediate stages
of the process may have increased clonal proliferation
rates relative to normal stem cells. Cigarette smokingin-
creases the rate at which cells undergo the first change
and the rate at which they undergo the penultimate
change (the one before, the final malignant change). Al-
though the epidemiological data appear to be consistent
with this theory, they do not prove its validity. Despite
this, the theory provides a framework within which to
predictfuture mortality associated withpresent and past
smokingrates, to analyze data on smokers' exposures to
othercarcinogens, and to evaluate thepotential effects of
intervention strategies. For example, Gaffney and Alt-
shuler (7) have noted that carcinogens that strongly af-
fect transition rates to an early stage in the multistage
process induce cancersthat occurlongafterexposure has
started. They are more dangerous than those that affect
only alate change, because years may elapse before they
are detected.
Known Carcinogens: Radiation
In 1947, atthefoundingofthe Institute ofEnvironmen-
tal Medicine, only2 years hadelapsed since the atomic ex-
plosions in Hiroshima and Nagasaki-a time insufficient
to appreciate the resultinglong-term carcinogenic effects.
The epidemics oflung cancer among uranium miners in
the U.S. and Czechoslovakia, although known to some,
were not widely appreciated. Since then the risks of
radiation-induced human cancers have been the subject
ofextensive research, much ofit contributed by investi-
gators at NYU. Several examples are particularly rele-
vanttotheissueswe arefacingtodayindealingwithrisks
from radon in homes.
Harley and Pasternack (10) postulated that the lung
cancerrate inducedbyasingleradonexposure isindepen-
dent oftime since exposure (after a short period during
which no cancers occur). These researchers were among
the first to note that radon-induced lung cancer rates in-
crease with age atfirst exposure, an observation now sup-
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FIGURE 3. Annual U.S. cigarette consumption in cigarettes per capita from 1920-1979 (0). U.S respiratory cancermortality rates forboth sexes com-
bined, from 6th or 7th International Classification ofDiseases (ICD) codes 162-164 for 1940-1959 -and 8th ICD code 162 for 1960-1979 (-). From
Kristein (44).
ported by the recent BEIR IV analysis offour cohorts of
miners (11). To account for this observation, Harley and
Pasternack revised their original formulation and postu-
lated instead that radon-induced rates decrease with time
since last exposure. However, recent follow-up of the
miner cohorts suggests that radon-induced rates do not
vary appreciably with time since cessation ofmining, in
agreement with Harley and Pasternack's original formu-
lation. Thus, the increase inriskwith age at exposure can-
not be explained by a waning or repair effect after ex-
posure ceases, as Harley and Pasternack con.jectured.
Peto (12) has proposed an alternative explanation that
allows the rates to remain constant with time since ex-
posure: Radon affects the penultimate stage in a mul-
tistage process. Thishypothesis, when combinedwiththe
theory describedpreviously fortobacco-inducedlung can-
cer,predicts that smokers havehigherradiation-induced
rates than do nonsmokers. This prediction appears to
agree withthe data(11). Peto'shypothesisimpliesthatra-
don is most damaging to the elderly and that reducing
residential radonlevels will have short-tern beneficial ef-
fects on lung cancer risk.
The data ontemporal effects ofother forms ofionizing
radiation are less clear. On the one hand, evidence from
the cohort ofatomie bomb survivors andthe cohortgiven
X-ray treatments for ankylosing spondylitis (13,14) indi-
cate excess rates that increase with age atirradiation and
that remain constant with time since irradiation. These
patterns suggest that a late-stage action also applies to
the induction of nonhormonal epithelial cancers by all
forms ofionizingradiation. However, the skin cancer data
among children given X-ray treatment for ringworm of
the scalp (15) indicate that radiation-induced rates in-
crease sharplywithtime since irradiation, atemporalpat-
tern more consistent with an early-stage effect ofradia-
tion. Further long-term follow-up of these irradiated
cohorts is needed to test Peto's conjecture.
The temporalbehaviorofradiation-induced breast can-
cerrates differs from that ofother epithelial cancers, ac-
cording to data from cohorts of atomic bomb survivors,
and ofwomen X-irradiated for postpartum mastitis and
tuberculosis (16,17). These suggest that risk is highest
among women who were irradiated during adolescence,
when breast epithelial cells are rapidly dividing. In con-
trastto the pictureforradon andlungcancer, the breast
cancer data also indicate that radiation-induced rates in-
crease with time since exposure, suggesting that radia-
tion induces an early neoplastic change in breast
epithelial cells.
Animportant goalforfuture workis to develop aunify-
ing theory for radiation-induced human carcinogenesis
that allows reliable predictions of risk among various
population subgroups. Thesepredictions areneededto de-
termine exposure limits and setpriorities forabatement
procedures.
All of the human data suggest that radiation-induced
cancer rates are proportional to radiation dose, at least
in the lower dose ranges. For radon, a linear dose-
response relationship implies relatively large lungcancer
risks associated with indoor levels in U.S. homes. In
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reviewingall oftherelevant epidemiological data, Thomas
and McNeill (18) estimated the lifetime probability of
radon-induced lung cancer to be 0.65 cancers per 1000
persons perworking-level month(WLM). Radonlevels in
many U.S. homes are about 1 picocurie per liter ofair (1
pCi/L), which produces an exposure roughly equivalent
to 0.25WLM peryear(19). Thus, 70years in ahomewith
1 pCi/L of radon gives an exposure of 70 x 0.25 = 17.5
WLM, and alifetime riskof 17.5 x 0.65 x 10-3 = 1.14%.
This risk estimate is an oversimplification: It is based
largely on data among smokers and must be reduced by
at least a factor of two for nonsmokers, it assumes that
risk is proportional to radiation dose, and it ignores the
age-at-exposure effects discussed earlier. Nevertheless, it
is useful in setting priorities. For example, it differs by
three orders of magnitude from the estimated lifetime
lung cancer probability of 1/100,000 associated with liv-
ing in a home containing nonfriable asbestos insulation
(20), afact ofrelevance when considering themerits ofex-
pending large sums to remove asbestos insulation from
public buildings.
Monitoring Risks from Potential
Carcinogens
Aninterdisciplinarygroup such asthe Institute ofEn-
vironmental Medicine provides an ideal setting for the
early detection ofhuman carcinogens, asillustratedbythe
history ofthe compound bischloromethyl ether (BCME)
(21). At NYU, Van Duuren and his colleagues studied
classes ofchemicals in order to relate chemical structure
toprobable carcinogenicity (22,23). The chlorinated ethers
were singled out, and rodent experiments determined
that BCME was the most carcinogenic. Because humans
inhale this compound inoccupational settings, furtherin-
halation studies inratswere conducted(24). These studies
indicated that BCME was alung carcinogen in rats. The
results prompted an epidemiologic study ofmen occupa-
tionally exposed to BCME, whichfound an excess oflung
cancer (25). The totality ofthis work prevented cancers
by allowing early introduction ofprotective measures.
The BCME experience and others like it raised hopes
that human cancer risks could be controlled by eliminat-
ing chemicals that testpositive in animal experiments. In
an invited address to NYU Medical Center in 1974 enti-
tled "Carcinogens areMutagens," BruceAmesraisedthe
furtherpossibility that short-term tests formutagenicity
and other genotoxic effects could screen for carcinogens
(26). Animal experiments couldbe supplemented or even
replaced by rapid and inexpensive test batteries that
would detecthuman carcinogenswithhighsensitivity and
specificity.
These hopes have notbeenrealized. Laboratoryexperi-
ments are still imperfect tools for detecting human can-
cer, for several reasons. Oneisthegreatvariability across
species in response to chemicals and our lack of under-
standing about the causes ofthis variability. The Inter-
national Agency for Research on Cancer has determined
thatthere is sufficient evidence from humanobservations,
butlimited, inadequate, ornonexistent evidence from an-
imal experiments to classify as carcinogens the com-
pounds listed in Thble 1. The fact thatmost ofthese com-
pounds have tested positive in one or more of the
short-termtestsreflects notthe sensitivity ofthetestbat-
tery, butratherthe intense scrutinythe compounds have
received relative to those for which no human data are
available.
Another shortcomingoflaboratory tests as screens for
human carcinogens istheirlackofspecificity; one ormore
ofthemhavetestedpositiveforanumberofchemicals oc-
curringnaturally in thefoods we eat andthe products we
use. Thislackofspecificityisrelatedtotheinabilityoflab-
oratory work to mimic the complex mix of carcinogens
and cocarcinogens to which human cells are exposed. We
now know that response to one carcinogen depends on
other exposures, endogenous hormone levels, and myriad
otherfactors. Workconducted at NYU andelsewhere has
revealed avarietyofpathways through which carcinogens
work on somatic cells. These include nucleareffects such
as the formation of DNA adducts and oncogene expres-
sion, and extranuclear effects such asmitotic acceleration.
Forexample, experimental mouse skin carcinogenesis in-
dicates thatthe dose-response curve forinitiating carcino-
gens can be altered by the presence ofother promoting
agents (27).
Forall ofthese reasons, laboratory tests do notyetpro-
vide areliable screen for human carcinogens, and human
data continue to be needed, despite the obvious desira-
bility of discovering hazards before human exposure to
them. In particular, occupationally exposed populations
should be monitored routinely for cancer risks, as
described in the next section. The most promising de-
velopments in the monitoring ofexposed populations in-
volve the use ofbiological exposure markers inblood, tis-
sue, urine, feces, hair, or nail samples, as discussed
elsewhere in this symposium (28). Such markers have the
potential to document exposure levels, identify andquan-
tify unusual susceptibility to environmental toxicants, de-
tect neoplastic precursors, andprovide etiologically sup-
portive links between exposure and disease.
Although early hopes for a simple and consistent labo-
ratory testbattery were overoptimistic, laboratory tests
nevertheless make important contributions torisk assess-
ment. Specifically, they provide chemical profiles useful
in evaluating potential human risks. This is not to imply
that such profiles canproduce precise estimates ofhuman
cancer numbers associated with low exposures. We still
have no scientificbasisfor such estimation, but in our ig-
norance we haveno choicebuttousetheprofilesforcrude
and comparative estimates of risk.
Forexample, recent riskestimates havebeenbased on
Table 1. Chemicals or industrial processes with sufficienta evidence
for carcinogenicity in humans but not in experimental animals.'
Manufacture of auramine
Underground mining of hematite
Manufacture ofisopropyl alcohol (strong acid process)
Nickel refining
aAs defined by theInternational Agency for Research on Cancer(41).
bThken from IARC (41).
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comparative potency, whereby chemicals are rankedrela-
tive to one another. Relative ranks in humans at low doses
are assumed equal to those in other test systems at ex-
perimental doses (30,31). This method has been used by
Albert and colleagues at the Environmental Protection
Agency to estimate human lung cancer risk from diesel
particulate emissions (30). Several investigators have pro-
posedthatweregard as deminimus those levels ofacar-
cinogen calculated to produce no more risk than that as-
sociated with an exposure we now tolerate, e.g., the
amount ofchloroform accepted in drinking water by the
Environmental Protection Agency (29,31). The calcula-
tions are based on estimated potencies relative to that of
chloroform. While not a panacea for the uncertainties
created by lack of scientific evidence, this procedure
seems arationalpro teemalternative to policies that effec-
tively ban the use of all animal carcinogens.
Laboratory experiments also are needed to validate bi-
ological markers ofhuman exposureby correlatingthem
with exposure and disease in controlled settings. Perhaps
most importantly, they provide insight and guidance
aboutcarcinogenicmechanismsthatisneededto motivate
observational studies in humans.
Future Challenges in Cancer
Prevention
The absence ofreliable laboratory screens for human
carcinogensmandates aggressivemonitoringofexposed
populations, such as certain occupational groups, patients
undergoingchemotherapy, andthose living nearnuclear
facilities and toxicwaste dumps. Inparticular, industrial
epidemiologists shouldworkwithindustry physicians in
keeping computerized, annually updated and linkable
medical, job, and smoking histories for all current and
former employees. Continued morbidity and mortality
monitoring after retirement is particularly important in
view ofincreasing trends in certain cancer rates among
older age groups that cannot be explained by increased
diagnostic accuracy(32). Doll(33) has observed that this
monitoringmakes sense fromthe industrialpoint ofview,
because most such studies would reveal no excess risk,
and the accumulated negative human evidence, coupled
with estimates of exposure levels for various agents,
would be useful in resisting overzealous regulation. The
monitoring also makes sense from the workers' point of
view, becausereal hazardswouldbe detectedearlierthan
they otherwise might be. Finally, it makes sense for the
public whowouldlearn thatprolonged exposure to many
agentsfeared harmful have notproduced observable hu-
man hazards.
While such monitoring is important in preventing fu-
ture cancerepidemics, it isunlikely to have muchimpact
on the existing cancer burden, which is dominated by
smoking-induced lung cancer and by cancer sites whose
causes are yet unknown. Figure 4 shows estimates ofthe
percentage ofall cancers diagnosed inthe U.S. in 1985 oc-
curring among the major sites for men and women
separately. Among men, cancers ofthe lung, bowel, and
PERCENT PERCENT
FIGURE 4. Estimated percentage of all incident cancers occurring by
site oforigin in U.S males orfemales in 1985, excludingnonmelanoma
skin cancer and carcinoma in situ (45).
prostate accountforabout 56% ofall new cancers (an 57%
ofall cancer deaths). Among women, cancers ofthe lung,
bowel, and breast comprise 52% of all new cancers (and
51% ofall cancer deaths). Thus, preventive strategies in
the U.S. and otherindustrialized countries mustfocus on
these cancer sites.
However, the past 40 years have seen disappointingly
slowprogress in amassingthe knowledge needed to pre-
vent cancers ofthe breast, prostate, and bowel. We have
fared better in understanding tobacco-induced lung car-
cinogenesis, and the U.S. and Great Britain have made
some progress in avoiding this preventable disease. Fig-
ure 5 shows amodestbut clear downwardtrendwithyear
of birth in age-specific lung cancer rates among young
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FIGURE 5. Age-specific lung cancer mortality rates in U.S. white male
cohorts (46).
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U.S. white males. Each successive birth cohort contains
fewer men who started smoking, and among those who
did, a higher proportion who smoked low tar cigarettes.
A different picture emerges for young women, whose
smokingprevalence has increasedwithin the pastfour de-
cades. The increasing rates among young women shown
in Figure 6 mark the start ofan alarming rise in female
lung cancers thatwill continue to manifest itselfinto the
twenty-first century.
Equally alarming is the widespread use of smokeless
tobacco by young men in the U.S. If not checked, this
practice bodes an epidemic of oral cancer in the coming
decades. Eliminatingtobacco consumption is amajor chal-
lenge in cancer prevention. In particular, all elementary
and secondary schools should include programs on ways
to cope withthe peerpressures oftobacco use and onthe
health consequences of tobacco use.
Results from both experimental and epidemiological
studies indicate that risk for cancers of the bowel and
prostate maybe amenable to manipulation bynutritional
factors. However, the full picture needed for prevention
has not yet emerged. The search for chemopreventive
foods is a worthwhile approach, because the prescription
ofcertain exposuresisinherently more appealingthanthe
proscription of others. Work at NYU and elsewhere on
the anticarcinogenic effects ofvitamin A and its precur-
sors, ofthe protease inhibitors in seeds and certainbeans
(34-37), and ofthe allyl sulfides in onion and garlic oils
(38) provide promising first steps in reducing risk for
these and other cancers.
.fOur current ignorance ofthe ways to prevent cancers
the breast, bowel, andprostate mandates increased ef-
forts to screen highriskpopulations (39,40). Information
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FIGURE 6. Age-specific lung cancermortality rates in U.S. white female
cohorts (46).
is needed to identify those for whom screening is most
warranted, to determine cost-efficient screening sched-
ules, and to devise incentives to ensure timely screening.
Armed with this information, industrial firms could pro-
vide older employees with free or low-cost screening for
cancers ofthe breast, cervix, colon, and skin. Those with
computer-based records could remind employees when
screening is due, and even offer monetary incentives for
timely screening.
In conclusion, the past 40 years have seen substantial
gains in knowledge of the cancer risks associated with
tobacco, radiation, asbestos, and certain chemicals. How-
ever, we have been slow to put this knowledge to use in
preventing cancers, particularly those associated with
tobacco consumption. Increased efforts are needed to
eliminate tobacco consumption and to encourage timely
screening amonghigh riskgroups. Research is needed to
findnutritional factors to prevent those malignancies that
accountforthebulkofcancers inthe western world. Until
laboratory tests can predict human risk more reliably,
epidemiological monitoring of exposed populations is
needed to protect against the unwitting introduction of
new carcinogens into the environment.
This work is dedicated to Norton Nelson, whose encouragement, in-
spiration, and leadership have motivated my research. Work was sup-
ported by NIH grant CA 23214, and by a grant to SIMS from the En-
vironmental Protection Agency.
REFERENCES
1. Doll, R., and Hill, A. B. Smoking and carcinoma of the lung. Br.
Med. J. ii: 739 (1950).
2. Levin, M. L., Goldstein, H., andGerhardt, R R. Cancerandtobacco
smoking. JAMA 143: 336-338 (1950).
3. Mills, C. A., and Porter, M. M. Ibbacco-smoking habits and cancer
of the mouth and respiratory system. Cancer Res. 10: 539-542
(1950).
4. Schrek, R., Baker, L. A., Ballard, G. P, and Dolgoff, S. Ibbacco
smoking as an etiologic factor in disease: Cancer. Cancer Res. 10:
49-58 (1950).
5. Wynder, E. L., and Graham, E. A. Ibbacco smoking as a possible
etiologic factor in bronchogenic carcinoma. JAMA 143: 329-336
(1950).
6. Van Duuren, B. L., and Goldschmidt, B. M. Cocarcinogenic and
tumor-promoting agents in tobacco carcinogenesis. J. Natl. Can.
Inst. 56: 1237-1242 (1976).
7. Gaffney, M., andAltshuler, B. Public health implications ofcarcino-
genic exposure under the multistage model. Am. J. Epidemiol. 124:
1021-1030 (1986).
8. Peto, R. Epidemiology, multistage models, and short-term muta-
genicity tests. In: Origins ofHuman Cancer, Book C, Human Risk
Assessment, Vol. 4 (H. H. Hiatt and J. D. Watson, Eds.), Cold
Spring Harbor Conferences on Cell Proliferation, ColdSpring Har-
bor Laboratory, Cold Spring Harbor, New York, 1977, pp.
1403-1428.
9. Whittemore, A. S. Effect of cigarette smoking in epidemiologic
studies oflung cancer. Stat. Med., 7: 223-238 (1988).
10. Harley, N. H., and Pasternack, B. S. A model for predicting lung
cancer risks induced by environmental levels ofradon daughters.
Health Phys. 40: 307-316 (1981).
11. Health Risks of Radon and Other Internally Deposited Alpha-
Emitters. BEIR IV. National Academy Press, Washington, DC,
1988.
12. Peto, J. Comments on "Modelling the relative and absolute risks
ofradiation-induced cancers" by C. R. Muirhead and S. C. DarbyCANCER RISKASSESSMENTAND PREVENTION 101
(J. R. Stat. Soc. A 150: 83-100, 1987). J. R. Stat. Soc. A 150: 104
(1987).
13. Darby, S. C., Nakashima, E., andKato, H. Aparallel analysis ofcan-
cer mortality among atomic bomb survivors and patients with
ankylosing spondylitisgiven X-raytherapy. JNCI 75: 1-21 (1985).
14. Darby, S. C., Doll, R., Gill, S. K., and Smith, P. F. Long-term mor-
tality afterasingletreatment coursewithX-raysinpatientstreated
for ankylosing spondylitis. Br. J. Cancer 55: 179-190 (1987).
15. Shore, R. E., Albert, R., Reed, M., Harley, N., andPasternack, B.
Skin cancer incidence among children irradiated forringworm of
the scalp. Radiat. Res. 100: 192-204 (1984).
16. Land, C. D., Boice, J. D., Shore, R. E., Norman, J. E., and
Ibkunaga, M. Breast cancer riskfrom low-dose exposure to ioniz-
ing radiation: Results ofparallel analysis ofthree exposed popu-
lations of women. J. Natl. Can. Inst. 65: 353-376 (1980).
17. Shore, R. E., Hildreth, N., Woodward, E., Dvoretsky, P., Hempel-
mann, L., and Pasternack, B. Breast cancer among women given
X-ray therapy for acute post-partum mastitis. JNCI 77: 689-696
(1986).
18. Thomas, D. C., McNeill, K. G., and Dougherty, C. Estimates oflung
cancer risks resulting from Rnprogeny exposure. Health Phys. 49:
825-846 (1985).
19. Nero, A. V., Schwehr, M. B., Nazaroff, W. W., and Revzan, K. L.
Distribution of airborne radon-222 concentrations. Science 234:
992-997 (1986).
20. Doll, R., and Peto, J. Effects on Health ofExposure ofAsbestos.
Health and Safety Commission. Her Majesty's Stationery Office,
London, 1985.
21. Nelson, N. Cancer prevention: Environmental, industrial, and oc-
cupational factors Cancer 47: 1065-1070 (1981).
22. Van Duuren, R L., Goldschmidt, B. M., KIatz, C., Langseth, L.,Mer-
cado, C., Sivak, A., and Zaldivar, R. a-Halo-ethers: A new type of
alkylatingcarcinogen(abstr. 80). Am. Ind. Hyg. Assoc. J. 29(suppl.):
110 (1968).
23. Van Duuren, B. L., Goldschmidt, B. M., and Seidman, I. Carcino-
genic activity of dii- and trifunctional alpha-chloro ethers and of
1,4-dichlorobutene-2 in ICR/Ha Swiss mice. Cancer Res. 35:
2553-2557 (1975).
24. Kuschner, M., Laskin, S, Drew, R. T., Cappiello, V., and Nelson, N.
Inhalation carcinogenicity ofalphahalo ethers: 3. Lifetime andlim-
ited period inhalation studies with bis(chloromethyl)ether at 0.1
ppm. Arch. Environ. Health 30: 73-77 (1975).
25. Albert, R. E., Pasternack, B. S, Shore, R. E., Lippmann, M., Nel-
son, N., andFerris, B. Mortalitypatterns amongworkers exposed
tochloromethyl ethers. Apreliminary report. Environ. Health Per-
spect. 11: 209-214 (1975).
26. Ames, B. N. Identifying environmental chemicals causing muta-
tions and cancer. Science 204: 587-593 (1979).
27. Burns, F., Albert, R., Altshuler, B., andMorris, E. Approach torisk
assessmentforgenotoxic carcinogensbased on datafromthe mouse
skin initiation-promotion model. Environ. Health Perspect. 50:
309-320 (1983).
28. Wogan, G. N. Markers ofexposure to carcinogens. Environ. Health
Perspect. 81: 9-17 (1989).
29. Ames, B. B., Magaw, R., andGold, L. S. Rankingpossible carcino-
genic hazards. Science 236: 271-280 (1987).
30. Albert, R. E., Lewtas, J., Nesnow, S., Thorslung, T. W., and An-
derson, E. Comparative potency method for cancer risk assess-
ment: Applications to diesel particulate emissions. Risk Anal. 3:
101-107 (1983).
31. Fiskel, J. Toward a de minimus policy in risk regulation. J. Risk
Anal. 5: 257-260 (1985).
32. Davis, D. L., Lilienfeld, A. D., Gittelsohn, A., and Scheckenbach,
M. E. Increasing trends in some cancers in older Americans: Fact
or artifact? Toxicol. Ind. Health 2: 127-144 (1986).
33. Doll, R. Relevance ofepidemiology to policies for the prevention
of cancer. J. Occup. Med. 23: 601-609 (1981).
34. Belman, S., Rossman, T., and Troll, W. Inhibition ofinitiation by
the protease inhibitors, antipain andleupeptin (abstr.) . Proc. Am.
Assoc. Cancer Res. 18: 32 (1977).
35. Troll, W., Wiesner, R., Shellabarger, C., Holtzman, S., and Stone,
J. 0. Soybean diet lowersbreast tumor incidence in irradiated rats.
Carcinogenesis 1: 469-472 (1980).
36. Yavelow, J., Gidlund, M., andTroll, W. Protease inhibitors from pro-
cessed legumes effectively inhibit superoxide generation in re-
sponse to TPA. Carcinogenesis 3: 135-138 (1982).
37. Troll, W., Fraenkel, K., andWiesner, R. Protease inhibitors as an-
ticarcinogens. JNCI 73: 1245-1250 (1984).
38. Belman, S Onion andgarlic oilsinhibit tumorpromotion. Carcino-
genesis- 4: 1063-1065 (1983).
39. Dubin, N. Effect ofdifferent mammographic radiation exposures
on predicted benefits ofscreening forbreast cancer. Stat. Med. 1:
14-24 (1982).
40. 1986 Cancer Facts and Figures. American Cancer Society, New
York, 1987.
41. IARC Monographs. Chemicals and Industrial Processes Associated
with Cancer in Humans, Vols. 1-20. International Agency for Re-
search on Cancer, Lyon, France, 1972-1979.
42. Doll, R., and Peto, R. Cigarette smokingandbronchial carcinoma
among regular smokers and lifelong nonsmokers. J. Epidemiol.
Commun. Health 32: 303-313 (1978).
43. Doll, R. The age distribution ofcancer: Implications formodels of
carcinogenesis. J. R. Soc. A. 134: 133-166 (1971).
44. Kristein, M. M. Forty Years of U.S. cigarette smoking and heart
disease and cancermortality rates. J. Chron. Dis. 37: 317-323(1984).
45. Silverberg, E. Cancer statistics. CA-A 35: 1935 (1985).
46. Vital Statistics ofthe US 1960-1979, Vol. II-Mortality,Part A. Na-
tional Center for Health Statistics, Hyattsville, MD, 1984.